Triumeq
abacavir sulfate / dolutegravir sodium / lamivudine
Table of contents
Overview
Triumeq is a medicine for treating infection with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). It is used in adults and adolescents over 12 years old who weigh at least 40 kg.
Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.
-
List item
Triumeq : EPAR - Medicine overview (PDF/127.03 KB)
First published: 15/10/2014
Last updated: 14/08/2020
EMA/134093/2020 -
-
List item
Triumeq : EPAR - Risk-management-plan summary (PDF/608.06 KB)
First published: 15/10/2014
Last updated: 14/09/2022
Authorisation details
Product details | |
---|---|
Name |
Triumeq
|
Agency product number |
EMEA/H/C/002754
|
Active substance |
|
International non-proprietary name (INN) or common name |
abacavir sulfate / dolutegravir sodium / lamivudine
|
Therapeutic area (MeSH) |
HIV Infections
|
Anatomical therapeutic chemical (ATC) code |
J05AR13
|
Publication details | |
---|---|
Marketing-authorisation holder |
ViiV Healthcare B.V.
|
Revision |
30
|
Date of issue of marketing authorisation valid throughout the European Union |
31/08/2014
|
Contact address |
Van Asch van Wijckstraat 55 H |
Product information
22/09/2022 Triumeq - EMEA/H/C/002754 - WS2334
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.
Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.